Bausch + Lomb

363 articles about Bausch + Lomb

• Bausch + Lomb Amends CEO Separation Agreement

  12/22/2022

  Bausch + Lomb Corporation announced that the Company and its CEO, Joseph C. Papa, have entered into an Amended and Restated Separation Agreement, pursuant to which Mr. Papa has agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board of Directors of the Company determines in its discretion or his successor is appointed, but no later than June 30, 2023.

• Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

  12/13/2022

  Bausch + Lomb Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. 

• Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards

  12/12/2022

  Bausch + Lomb Corporation today announced its first-of-its-kind ONE by ONE and Biotrue Eye Care Recycling programs have been named a gold winner in the Most Environmentally Friendly Service of the Year category by the 2022 Best in Biz Awards.

• Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference

  11/7/2022

  Bausch + Lomb Corporation, today announced that Joseph C. Papa , chief executive officer, and Sam Eldessouky , executive vice president and chief financial officer are scheduled to participate at the 5th Annual Evercore ISI HealthCONx Conference on Nov. 30, 2022, at 9:40 a.m. ET.

• Bausch + Lomb Announces Third-Quarter 2022 Results

  11/2/2022

  Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2022 financial results.

• Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs

  10/24/2022

  Bausch + Lomb Corporation today announced the introduction of Project Watson health care products for dogs in the United States.

• Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2

  10/4/2022

  Bausch + Lomb Corporation will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022.

• Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

  9/27/2022

  Bausch + Lomb Corporation announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.

• Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

  9/26/2022

  Bausch + Lomb Corporation today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago from Sept. 30 to Oct. 3, 2022.

• Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings

  9/21/2022

  Bausch + Lomb Corporation today announced that data from the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2).

• First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+

  9/13/2022

  Bausch + Lomb Corporation released a report of survey results from the company's first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the 'blind spots' that may exist in the understanding and awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

• Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes

  9/1/2022

  Bausch + Lomb Corporation and Alfa Instruments s.r.l. announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes, Vitreocare, globally with the exception of Italy, where Alfa Instruments is based.

• Bausch + Lomb Announces Participation at Upcoming Investor Conferences

  8/29/2022

  Bausch + Lomb Corporation, today announced that Joseph C. Papa, Sam Eldessouky and Arthur J. Shannon are scheduled to participate at the Wells Fargo 2022 Healthcare Conference in Boston on Sept. 7, 2022 1:55 p.m. ET and at the 20th Annual Morgan Stanley Global Healthcare Conference in New York on Sept. 13, 2022 at 10:00 a.m. ET.

• Bausch Health Continuing Process Toward Separating Bausch + Lomb

  8/22/2022

  Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb") to an existing wholly-owned unrestricted subsidiary of the Company (the "Internal Transfer").

• Bausch + Lomb Announces Second-Quarter 2022 Results

  8/4/2022

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced its second-quarter 2022 financial results.

• Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma

  7/28/2022

  Bausch + Lomb Has Made an Equity Investment in Sanoculis and Has Entered into an Exclusive European Distribution Agreement for MIMS® Minimally Invasive Surgical Procedure.

• Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism

  7/26/2022

  Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas® TENEO™ excimer laser* for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism.

• Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4

  7/25/2022

  Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.

• Bausch + Lomb Provides Leadership Update

  7/20/2022

  Bausch + Lomb Corporation announced Joseph C. Papa has stepped down as chair of the Board of Directors of the Company (the "Board").

• Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

  7/6/2022

  Five Presentations Will Highlight Findings from the XIPERE ® Pivotal Phase 3 Program.